Prevention Trials

 

• STUDY10077
  
  NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)
  
  Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 500 to 1000 mg/m2 BID on each day of study. This study will focus on the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to prevent recurrence.
  
  Study Information

  ---

  
  

• STUDY15040
  
  Contingency Management to Promote Smoking Abstinence in Cancer Patients
  
  To compare tobacco abstinence rates in the preoperative period for cancer patients who smoke and receive a Contingency Management (CM) intervention (monetary payment contingent on abstinent breath CO + counseling + NRT) versus a Standard Care (SC) intervention (breath CO monitoring with no payment for abstinence + counseling + NRT).
  
  Study Information

  ---

  
  

• STUDY15916
  
  A Translational Randomized Clinical Trial of Varenicline Sampling to Promote Smoking Cessation and Scalable Treatment Dissemination
  
  This clinical trial examines what happens when current smokers are given a free sample of varenicline or nicotine replacement products (patches or lozenges) to help stop or reduce smoking. Smoking causes a number of deaths and diseases, including heart disease and cancer. All smokers are advised to quit. Varenicline is a drug that both reduces cravings for and decreases the pleasurable effects of cigarettes and other tobacco products. Nicotine replacement products reduce cravings for cigarettes. Information gained from this study may help researchers evaluate new methods of how varenicline affects smoking behavior.
  
  Study Information

  ---

  
  

• STUDY18956
  
  Hybrid Type 1 Effectiveness Implementation Trial of a Proactive Smoking Cessation Electronic Visit for Scalable Delivery via Primary Care
  
  We will conduct a two-arm clinic-randomized clinical trial (N=672) to examine the effectiveness of a smoking cessation electronic visit (e-visit) vs. treatment as usual (TAU) for smoking cessation across 21 MUSC primary care practices. Main outcomes include: 1) evidence-based smoking cessation treatment utilization (medication, psychosocial cessation counseling), 2) reduction in cigarettes per day, and 3) biochemically verified 7-day PPA at six-month follow-up. We hypothesize that smokers randomized to the e-visit condition will have significantly better cessation outcomes relative to TAU. Secondary outcomes will focus on implementation of the e-visit at the patient, provider, and organizational levels.
  
  Study Information

  ---

  
  

• STUDY19156
  
  A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers
  
  This phase II trial studies how well green tea catechins work in preventing progression of prostate cancer from a low risk stage to higher risk stages in men who are on active surveillance. Green tea catechins may stabilize prostate cancer and lower the chance of prostate growing.
  
  Study Information

  ---